1887

Abstract

Glycoprotein B (gB) of human cytomegalovirus (HCMV) is the dominating protein in the envelope of this virus and gives rise to virus-neutralizing antibodies in most infected individuals. We have previously isolated a neutralizing human antibody specific for antigenic domain 2 (AD-2) on gB, a poorly immunogenic epitope, which nevertheless is capable of eliciting potent neutralizing antibodies. In order to define parameters important for the neutralization of HCMV via gB, we have investigated the virus-neutralizing capacity and the kinetics of the interaction with AD-2 of the monomeric and dimeric forms of a single chain variable fragment (scFv) corresponding to this antibody. We demonstrate here that neutralization of HCMV via AD-2 on gB can be mediated by dimeric scFv, while monomeric fragments cannot mediate neutralization of the virus, despite a slow dissociation from the intact glycoprotein. This finding is discussed in the context of possible mechanisms for antibody-mediated virus neutralization.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-8-2001
2002-08-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/8/0832001a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-8-2001&mimeType=html&fmt=ahah

References

  1. Ayata, M., Sugano, T., Murayama, T., Sakamuro, D., Takegami, T., Matsumoto, Y. & Furukawa, T. ( 1994; ). Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. Journal of Medical Virology 43, 386-392.[CrossRef]
    [Google Scholar]
  2. Azuma, J., Kurimoto, T., Tsuji, S., Mochizuki, N., Fujinaga, S., Matsumoto, Y. & Masuho, Y. ( 1991; ). Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. Journal of Immunotherapy 10, 278-285.[CrossRef]
    [Google Scholar]
  3. Britt, W. J. & Vugler, L. G. ( 1992; ). Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). Journal of Virology 66, 6747-6754.
    [Google Scholar]
  4. Britt, W. J., Vugler, L., Butfiloski, E. J. & Stephens, E. B. ( 1990; ). Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology 64, 1079-1085.
    [Google Scholar]
  5. Burton, D. R., Williamson, R. A. & Parren, P. W. ( 2000; ). Antibody and virus: binding and neutralization. Virology 270, 1-3.[CrossRef]
    [Google Scholar]
  6. Burton, D. R., Saphire, E. O. & Parren, P. W. ( 2001; ). A model for neutralization of viruses based on antibody coating of the virion surface. Current Topics in Microbiology and Immunology 260, 109-143.
    [Google Scholar]
  7. Drew, P. D., Moss, M. T., Pasieka, T. J., Grose, C., Harris, W. J. & Porter, A. J. ( 2001; ). Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not. Journal of General Virology 82, 1959-1963.
    [Google Scholar]
  8. Fowler, K. B., Stagno, S., Pass, R. F., Britt, W. J., Boll, T. J. & Alford, C. A. ( 1992; ). The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New England Journal of Medicine 326, 663-667.[CrossRef]
    [Google Scholar]
  9. Ho, M. (1991). Cytomegalovirus: Biology and Infection, 2nd edn, pp. xix, 440. New York: Plenum Medical Book Company.
  10. Hopp, T. P., Pricket, K. S., Price, V. L., Libby, R. T., March, C. J., Cerretti, D. P., Urdal, D. L. & Conlon, P. J. ( 1988; ). A short polypeptide marker sequence useful for recombinant protein identification and purification. Bio-Technology 6, 1204-1210.[CrossRef]
    [Google Scholar]
  11. Kalinke, U., Krebber, A., Krebber, C., Bucher, E., Plückthun, A., Zinkernagel, R. M. & Hengartner, H. ( 1996; ). Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. European Journal of Immunology 26, 2801-2806.[CrossRef]
    [Google Scholar]
  12. Loenen, W. A., Bruggeman, C. A. & Wiertz, E. J. ( 2001; ). Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Seminars in Immunology 13, 41-49.[CrossRef]
    [Google Scholar]
  13. Masuho, Y., Matsumoto, Y., Sugano, T., Fujinaga, S. & Minamishima, Y. ( 1987; ). Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology 68, 1457-1461.[CrossRef]
    [Google Scholar]
  14. Meyer, H., Sundqvist, V. A., Pereira, L. & Mach, M. ( 1992; ). Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology 73, 2375-2383.[CrossRef]
    [Google Scholar]
  15. Navarro, D., Lennette, E., Tugizov, S. & Pereira, L. ( 1997; ). Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. Journal of Medical Virology 52, 451-459.[CrossRef]
    [Google Scholar]
  16. Ohizumi, Y., Suzuki, H., Matsumoto, Y., Masuho, Y. & Numazaki, Y. ( 1992; ). Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. Journal of General Virology 73, 2705-2707.[CrossRef]
    [Google Scholar]
  17. Ohlin, M., Sundqvist, V. A., Mach, M., Wahren, B. & Borrebaeck, C. A. K. ( 1993; ). Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. Journal of Virology 67, 703-710.
    [Google Scholar]
  18. Ohlin, M., Owman, H., Mach, M. & Borrebaeck, C. A. K. ( 1996; ). Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Molecular Immunology 33, 47-56.[CrossRef]
    [Google Scholar]
  19. Roost, H. P., Bachmann, M. F., Haag, A., Kalinke, U., Pliska, V., Hengartner, H. & Zinkernagel, R. M. ( 1995; ). Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proceedings of the National Academy of Sciences, USA 92, 1257-1261.[CrossRef]
    [Google Scholar]
  20. Roy, D. M. & Grundy, J. E. ( 1992; ). Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations. Transplantation 54, 1109-1110.[CrossRef]
    [Google Scholar]
  21. Schoppel, K., Kropff, B., Schmidt, C., Vornhagen, R. & Mach, M. ( 1997; ). The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. Journal of Infectious Diseases 175, 533-544.[CrossRef]
    [Google Scholar]
  22. Snydman, D. R., Werner, B. G., Meissner, H. C., Cheeseman, S. H., Schwab, J., Bednarek, F., Kennedy, J. L., Jr, Herschel, M., Magno, A., Levin, M. J. and others ( 1995; ). Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatric Infectious Disease Journal 14, 34–40.[CrossRef]
    [Google Scholar]
  23. Spaete, R. R. ( 1991; ). A recombinant subunit vaccine approach to HCMV vaccine development. Transplantation Proceedings 23, 90-96.
    [Google Scholar]
  24. Spaete, R. R., Gehrz, R. C. & Landini, M. P. ( 1994; ). Human cytomegalovirus structural proteins. Journal of General Virology 75, 3287-3308.[CrossRef]
    [Google Scholar]
  25. Thorpe, R., Bird, C. R. & Brasher, M. D. ( 1987; ). Characterisation, standardisation and control of therapeutic immunoglobulin preparations intended for intravenous use. Journal of Infection 15, 13-19.[CrossRef]
    [Google Scholar]
  26. Utz, U., Britt, W., Vugler, L. & Mach, M. ( 1989; ). Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology 63, 1995-2001.
    [Google Scholar]
  27. Zaia, J. A. ( 1993; ). Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clinical Infectious Diseases 17 (Suppl. 2), S392–S399.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-8-2001
Loading
/content/journal/jgv/10.1099/0022-1317-83-8-2001
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error